Steven S. Williamson Sells 9,648 Shares of Pulmonx (NASDAQ:LUNG) Stock

Key Points

• Steven Williamson, CEO of Pulmonx, sold 9,648 shares at an average price of $1.60, reducing his ownership by 2.62%, leaving him with approximately $574,347 worth of stock.
• Shares of Pulmonx (NASDAQ:LUNG) experienced a recent decline, trading down $0.07 to $1.66, with a market cap of $67.65 million.
• Analysts have varied ratings on Pulmonx, with a consensus rating of "Moderate Buy" and target prices ranging from $2.50 to $8.00 following recent downgrades from Piper Sandler and upgrades from Wall Street Zen.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) CEO Steven S. Williamson sold 9,648 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $1.60, for a total value of $15,436.80. Following the sale, the chief executive officer directly owned 358,967 shares in the company, valued at approximately $574,347.20. The trade was a 2.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pulmonx Stock Down 2.3%

NASDAQ LUNG traded down $0.04 during trading on Monday, hitting $1.70. The company's stock had a trading volume of 376,522 shares, compared to its average volume of 653,362. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.35 and a quick ratio of 4.63. The company has a market cap of $69.28 million, a PE ratio of -1.19 and a beta of 0.43. The business's 50 day simple moving average is $2.23 and its 200-day simple moving average is $4.04. Pulmonx Corporation has a fifty-two week low of $1.47 and a fifty-two week high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.02. The firm had revenue of $23.86 million during the quarter, compared to the consensus estimate of $23.46 million. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%. Pulmonx has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Pulmonx Corporation will post -1.55 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. D. Boral Capital reaffirmed a "buy" rating and issued a $16.00 price target on shares of Pulmonx in a research note on Monday. Piper Sandler lowered Pulmonx from an "overweight" rating to a "neutral" rating and lowered their price objective for the stock from $9.00 to $2.50 in a research note on Thursday, July 31st. Lake Street Capital lowered their price objective on Pulmonx from $12.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. Stifel Nicolaus lowered their price objective on Pulmonx from $16.00 to $5.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. Finally, Wells Fargo & Company decreased their price target on Pulmonx from $6.00 to $3.00 and set an "equal weight" rating on the stock in a research note on Friday, August 1st. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, Pulmonx has an average rating of "Moderate Buy" and an average price target of $7.66.

Institutional Investors Weigh In On Pulmonx

Several large investors have recently bought and sold shares of the stock. Rhumbline Advisers increased its holdings in Pulmonx by 4.6% during the 1st quarter. Rhumbline Advisers now owns 55,958 shares of the company's stock worth $377,000 after purchasing an additional 2,455 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Pulmonx by 1.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 320,946 shares of the company's stock valued at $2,160,000 after purchasing an additional 5,414 shares during the period. Wells Fargo & Company MN boosted its position in shares of Pulmonx by 48.7% in the 4th quarter. Wells Fargo & Company MN now owns 18,418 shares of the company's stock valued at $125,000 after purchasing an additional 6,033 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Pulmonx in the 4th quarter valued at about $43,000. Finally, Graham Capital Management L.P. boosted its position in shares of Pulmonx by 73.3% in the 4th quarter. Graham Capital Management L.P. now owns 18,071 shares of the company's stock valued at $123,000 after purchasing an additional 7,641 shares during the period. Hedge funds and other institutional investors own 91.04% of the company's stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.